Shelton Capital Management Acquires New Shares in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Posted by Defense World Staff on Jun 10th, 2023

Shelton Capital Management bought a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,687 shares of the life sciences company’s stock, valued at approximately $207,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Integra LifeSciences by 89.3% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 1,512,652 shares of the life sciences company’s stock worth $84,814,000 after buying an additional 713,454 shares during the last quarter. Cooke & Bieler LP boosted its holdings in Integra LifeSciences by 9.6% in the 3rd quarter. Cooke & Bieler LP now owns 2,732,859 shares of the life sciences company’s stock valued at $115,764,000 after purchasing an additional 239,485 shares during the period. Balyasny Asset Management LLC acquired a new stake in Integra LifeSciences in the 3rd quarter worth $8,984,000. Great Lakes Advisors LLC bought a new position in shares of Integra LifeSciences during the 4th quarter worth about $1,066,000. Finally, Vanguard Group Inc. lifted its stake in shares of Integra LifeSciences by 2.8% in the third quarter. Vanguard Group Inc. now owns 6,929,606 shares of the life sciences company’s stock valued at $293,538,000 after buying an additional 189,772 shares during the period. Institutional investors and hedge funds own 87.60% of the company’s stock.

Insider Activity at Integra LifeSciences

In other Integra LifeSciences news, CEO Witte Jan De bought 7,792 shares of the firm’s stock in a transaction dated Thursday, June 1st. The shares were bought at an average price of $38.50 per share, for a total transaction of $299,992.00. Following the completion of the acquisition, the chief executive officer now owns 12,798 shares of the company’s stock, valued at $492,723. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.20% of the company’s stock.

Integra LifeSciences Stock Down 0.8 %

IART opened at $40.62 on Friday. The firm has a market cap of $3.33 billion, a price-to-earnings ratio of 19.72, a PEG ratio of 1.32 and a beta of 1.16. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.40 and a current ratio of 3.65. The firm’s 50-day simple moving average is $50.20 and its 200-day simple moving average is $54.07. Integra LifeSciences Holdings Co. has a twelve month low of $37.36 and a twelve month high of $60.69.

Integra LifeSciences (NASDAQ:IART – Get Rating) last issued its quarterly earnings data on Wednesday, April 26th. The life sciences company reported $0.74 earnings per share for the quarter, hitting the consensus estimate of $0.74. Integra LifeSciences had a net margin of 11.00% and a return on equity of 16.29%. The firm had revenue of $380.85 million for the quarter, compared to analysts’ expectations of $373.21 million. During the same period in the prior year, the firm earned $0.74 earnings per share. The company’s quarterly revenue was up 1.1% compared to the same quarter last year. Equities research analysts anticipate that Integra LifeSciences Holdings Co. will post 3.23 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on IART. Truist Financial lowered their price target on Integra LifeSciences from $54.00 to $44.00 in a research note on Tuesday, May 30th. JMP Securities cut their target price on Integra LifeSciences from $75.00 to $65.00 in a research note on Thursday, April 27th. JPMorgan Chase & Co. downgraded shares of Integra LifeSciences from a “neutral” rating to an “underweight” rating and decreased their price target for the stock from $56.00 to $43.00 in a research note on Wednesday, May 24th. StockNews.com began coverage on shares of Integra LifeSciences in a research note on Thursday, May 18th. They issued a “buy” rating for the company. Finally, 22nd Century Group reiterated a “downgrade” rating on shares of Integra LifeSciences in a research report on Tuesday, May 23rd. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Integra LifeSciences presently has a consensus rating of “Hold” and a consensus target price of $49.71.

Integra LifeSciences Company Profile

(Get Rating)

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology.